First-dose effects of fingolimod: Pooled safety data from three phase 3 studies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

First-dose effects of fingolimod: Pooled safety data from three phase 3 studies

Published:2014-09 Issue:5 Volume:3 Page:629-638
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

DiMarco John P.,O’Connor Paul,Cohen Jeffrey A.,Reder Anthony T.,Zhang-Auberson Lixin,Tang Dejun,Collins William,Kappos Ludwig

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference20 articles.

1. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology;Brinkmann;Pharmacol Ther,2007

2. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis;Brinkmann;Nat Rev Drug Discov,2010

3. Efficacy and safety of fingolimod in patients with relapsing-remitting multiple sclerosis: results from the 24-month phase 3 double-blind, randomised, placebo-controlled study (FREEDOMS II);Calabresi;Lancet Neurol,2014

4. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis;Chun;Clin Neuropharmacol,2010

5. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis;Cohen;N Engl J Med,2010

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of fingolimod in patients with relapsing remitting multiple sclerosis: A descriptive analysis of data from the EudraVigilance database;Journal of the Neurological Sciences;2024-08

2. Pre-existing parasympathetic dominance seems to account for heart rate slowingafter six months of Fingolimod-treatment in patients with multiple sclerosis;2024-03-12

3. Index of cardiac-electrophysiological balance in relapsing–remitting multiple sclerosis patients treated with fingolimod;Multiple Sclerosis and Related Disorders;2023-08

4. Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis;Pharmacology & Therapeutics;2023-06

5. Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs;Alimentary Pharmacology & Therapeutics;2023-04-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3